{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:29:41Z","timestamp":1787671781158,"version":"build-2736575974"},"reference-count":21,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Epcoritamab is a US Food and Drug Administration\u2013approved bispecific antibody for relapsed\/refractory (R\/R) large B-cell lymphomas (BCLs). Real-world outcomes and safety data remain limited. We analyzed 157 adult patients with R\/R aggressive BCLs who received epcoritamab outside of a clinical trial between 2023 and 2025 at 9 centers in the Collaborative US Bispecific Consortium. The best overall response rate (ORR) was 49.6%, and the best complete response rate (CRR) was 31.9%. With a median follow-up of 15.8 months, the 1-year progression-free survival (PFS) and overall survival (OS) rates among all patients were 29% (95% confidence interval [CI], 22-37) and 38% (95% CI, 31-47), respectively. Inferior ORRs and CRRs were observed in patients with high International Prognostic Index, elevated lactate dehydrogenase (LDH), \u22652 extranodal sites, and disease refractory to the previous line of therapy (LOT). In multivariable analysis, Eastern Cooperative Oncology Group performance status score of \u22652, elevated LDH, refractory disease to previous LOT, and clinical trial ineligibility were associated with inferior PFS and OS. Among all patients, 33% had any-grade cytokine release syndrome (CRS; grade \u22653, 4.6%), whereas immune effector cell\u2013associated neurotoxicity syndrome (ICANS) occurred in 12% (grade \u22653, 0.6%) of patients. Intensive care unit (ICU) admission occurred in 17% of patients. Compared with pivotal trials and other real-world studies, we observed inferior response rates and survival outcomes as well as higher rates of grade \u22653 CRS, any-grade ICANS, and ICU admission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020171","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:16:41Z","timestamp":1781043401000},"page":"5496-5504","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors and survival outcomes in relapsed\/refractory aggressive B-cell lymphomas treated with epcoritamab"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3174-8877","authenticated-orcid":false,"given":"Allison M.","family":"Bock","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-8046","authenticated-orcid":false,"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"2Division of Cancer Medicine, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Chauhan","sequence":"additional","affiliation":[{"name":"3Division of Cancer Medicine, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-3838","authenticated-orcid":false,"given":"Lorenzo","family":"Falchi","sequence":"additional","affiliation":[{"name":"4Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Merryman","sequence":"additional","affiliation":[{"name":"5Division of Lymphoma, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Godbole","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha K.","family":"Thiruvengadam","sequence":"additional","affiliation":[{"name":"7Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-7942","authenticated-orcid":false,"given":"Andrew P.","family":"Jallouk","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Major","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Department of Medicine, University of Colorado Anschutz School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"10Division of Oncology and Hematology, Department of Internal Medicine, Fred & Pamela Buffett Cancer Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Ayers","sequence":"additional","affiliation":[{"name":"3Division of Cancer Medicine, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8115-7322","authenticated-orcid":false,"given":"Kelsey","family":"Baron","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omnia M.","family":"Farahat","sequence":"additional","affiliation":[{"name":"3Division of Cancer Medicine, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-5713","authenticated-orcid":false,"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[{"name":"7Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Danilov","sequence":"additional","affiliation":[{"name":"7Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0094-0014","authenticated-orcid":false,"given":"Steven","family":"Bair","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Department of Medicine, University of Colorado Anschutz School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[{"name":"10Division of Oncology and Hematology, Department of Internal Medicine, Fred & Pamela Buffett Cancer Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakthi","family":"Bhaskar","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"7Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-3671","authenticated-orcid":false,"given":"Yazeed","family":"Sawalha","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"3Division of Cancer Medicine, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Crombie","sequence":"additional","affiliation":[{"name":"5Division of Lymphoma, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"4Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"3Division of Cancer Medicine, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"4","key":"2026082510513765600_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"2026082510513765600_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"16","key":"2026082510513765600_bib3","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2026082510513765600_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood-2023-174497","article-title":"Effectiveness of chemo-immunotherapy (CIT) and novel therapies in second or later line of therapy (2L+) for patients with relapsed\/refractory (R\/R) aggressive large B-cell lymphoma (LBCL)","volume":"142","author":"Nastoupil","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026082510513765600_bib5","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"2026082510513765600_bib6","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026082510513765600_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2024-199330","article-title":"Real-world outcomes with bispecific T-cell engagers (REALBiTE) for relapsed or refractory large B-cell lymphoma: a multi-center, retrospective cohort study","volume":"144","author":"Brooks","year":"2024","journal-title":"Blood"},{"key":"2026082510513765600_bib8","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1002\/hon.70094_326","article-title":"Glofitamab and epcoritamab for large B cell lymphoma in 319 real world patients: a retrospective UK analysis of efficacy, tolerability and practical implications [abstract]","volume":"43","author":"Haynes","year":"2025","journal-title":"Hematological Oncology"},{"issue":"27","key":"2026082510513765600_bib9","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026082510513765600_bib10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2026082510513765600_bib11","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med Overseas Ed"},{"issue":"15","key":"2026082510513765600_bib12","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/bloodadvances.2024014903","article-title":"Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"2026082510513765600_bib13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"22","key":"2026082510513765600_bib14","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026082510513765600_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"27","key":"2026082510513765600_bib16","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"2026082510513765600_bib17","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2026082510513765600_bib18","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2352-3026(25)00327-8","article-title":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial","volume":"13","author":"Kater","year":"2026","journal-title":"The Lancet Haematology"},{"issue":"33","key":"2026082510513765600_bib19","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research statement","volume":"35","author":"Kim","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"2026082510513765600_bib20","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood.2024026830","article-title":"Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial","volume":"145","author":"Brody","year":"2025","journal-title":"Blood"},{"issue":"suppl 16","key":"2026082510513765600_bib21","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1200\/JCO.2022.40.16_suppl.7528","article-title":"Subcutaneous epcoritamab + R-DHAX\/C in patients (pts) with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): preliminary phase 1\/2 results","volume":"40","author":"Abrisqueta","year":"2022","journal-title":"Journal of Clinical Oncology"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5496\/2537424\/blooda_adv-2026-020171-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5496\/2537424\/blooda_adv-2026-020171-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:53:01Z","timestamp":1787669581000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/16\/5496\/568886\/Prognostic-factors-and-survival-outcomes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":21,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020171","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,25]]},"published":{"date-parts":[[2026,8,12]]}}}